ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/AXL-inhibitor

Search results

target/AXL-inhibitor
12 trial(s) found.
NCT07489495
NCT07293351
NCT07227402
NCT07011719
NCT06943755
NCT05691478
NCT05536141
NA
NA
NCT05327686
NCT05176483
NCT04293562
NCT03409081
ACTRN12624000082505
Filters
AXL
100%
MET
75%
VEGFR2
75%
KIT
50%
RET
50%
ROS1
50%
VEGFR
50%
HIF2a
33%
MER
33%
CTLA4
33%
PD-1/PD-L1
33%
PD-1
25%
FLT3
25%
PD-L1
17%
VEGFA
8%
mTOR
8%
mTORC1
8%
PDGFR
8%
VEGF
8%
LAG3
8%
CD33
8%
Bcl2
8%
NA 




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.